The Effect of Anesthesia on Systemic Inflammatory Immune Index in Major Abdominal Cancer Surgeries

May 14, 2021 updated by: Arsen Güngör, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

The Effect of Inhalation Anesthesia and Total Intravenous Anesthesia on Systemic Inflammatory Immune Index in Major Abdominal Cancer Surgeries

The effects of different anesthesia methods on the immune system are variable. In this study, we investigated the effect of inhalation anesthesia and total intravenous anesthesia on the SII value in major abdominal cancer surgeries.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study was planned prospectively, observationally, on a total of 90 patients who underwent major abdominal cancer surgery. 84 patients were evaluated. The patients were seperated in two groups as inhalation anesthesia and total intravenous anesthesia (TIVA). The demographic data of the patients, type of cancer, type of surgery performed, ASA classification, preoperative chemotherapy intake, preoperative hemogram, postoperative 2nd and 24th hour hemogram, intraoperative and postoperative blood transfusion, and duration of surgery were recorded. Platelet, neutrophil, lymphocyte and SII values were saved.

Study Type

Observational

Enrollment (Actual)

84

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Yenimahalle
      • Ankara, Yenimahalle, Turkey, 06200
        • Dr. Abdurrahman Yurtaslan Oncology Research and Trainee Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

major abdominal cancer patients between 18-85 years included. 40 patients in sevoflurane group and 44 patients in TIVA group collected

Description

Inclusion Criteria:

  • major abdominal cancer surgeries

Exclusion Criteria:

  • blood transfusion in last 72 hours
  • patients with infection
  • hematologic malignancy
  • patient controlled analgesia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Inhalation anesthesia
Sevoflurane for opioid remifentanyl used
Other: Systemic inflammatory immmune index
Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
Total Intravenous Anesthesia
Propofol for opioid remifentanyl used
Other: Systemic inflammatory immmune index
Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value
Time Frame: preoperative SII noted, postoperative 2.hour noted and postoperative 24.hour noted
systemic inflammatory immune index calculated by (platelet x neutrophil)/lymphocyte
preoperative SII noted, postoperative 2.hour noted and postoperative 24.hour noted

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Investigators

  • Principal Investigator: Arsen Gungor, arsen.gungor@hotmail.com

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2020

Primary Completion (Actual)

September 15, 2020

Study Completion (Actual)

December 12, 2020

Study Registration Dates

First Submitted

March 17, 2021

First Submitted That Met QC Criteria

May 14, 2021

First Posted (Actual)

May 18, 2021

Study Record Updates

Last Update Posted (Actual)

May 18, 2021

Last Update Submitted That Met QC Criteria

May 14, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AbdurrahmanYAOTRH (Other Identifier: Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

shared after published

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer of Endometrium

Clinical Trials on Systemic inflammatory immmune index

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe